List of Epidiolex drug patents
Epidiolex is owned by Gw Res Ltd.
Epidiolex contains Cannabidiol.
Epidiolex has a total of 26 drug patents out of which 1 drug patent has expired.
Expired drug patents of Epidiolex are:
- US10195159
Epidiolex was authorised for market use on 28 September, 2018.
Epidiolex is available in solution;oral dosage forms.
Epidiolex can be used as use for the treatment of convulsive seizures in patients with lennox gastaut syndrome, use for the treatment of drop seizures in patients with dravet syndrome; use for the treatment of drop seizures in patients with lennox-gastaut syndrome, use for the treatment of seizures in patients with lennox-gastaut syndrome; use for the treatment of seizures in patients with dravet syndrome; use for reducing convulsive seizure frequency in patients with lennox gastaut syndrome; use for reducing convulsive seizure frequency in patients with dravet syndrome, use for the treatment of seizures in patients with dravet syndrome; use for the treatment of seizures in patients with lennox-gastaut syndrome, use for the treatment of generalized seizures or focal seizures with impairment in patients with tuberous sclerosis complex; use for the treatment of seizures in patients with tuberous sclerosis complex; use for reducing seizure frequency in patients with tuberous sclerosis complex, use for the treatment of seizures in patients with lennox-gastaut syndrome; use for the treatment of seizures in patients with dravet syndrome, use in combination with clobazam for the treatment of seizures in patients with dravet syndrome, use for the treatment of atonic seizures in patients with dravet syndrome; use for the treatment of atonic seizures in patients with lennox-gastaut syndrome, use for the treatment of focal seizures in patients with dravet syndrome, use for the treatment of absence seizures in patients with dravet syndrome; use for the treatment of absence seizures in patients with lennox-gastaut syndrome, use in combination with clobazam for treatment of seizures in patients with lennox gastaut syndrome, use for the treatment of seizures associated with dravet syndrome; use for the treatment of seizures associated with lennox-gastaut syndrome, use for the treatment of seizures in patients with tuberous sclerosis complex, use for the treatment of drop seizures in patients with dravet syndrome, use for the treatment of convulsive seizures in patients with dravet syndrome, use for the treatment of drop seizures in patients with lennox-gastaut syndrome; use in combination with clobazam for treatment of drop seizures in patients with lennox gastaut syndrome, use in combination with clobazam for the treatment of seizures in patients with lennox gastaut syndrome who have been previously treated with clobazam; use in combination with clobazam for the treatment of seizures in patients with dravet syndrome who have been previously treated with clobazam, use for the treatment of seizures in patients with lennox-gastaut syndrome; use for the treatment of seizures in patients with dravet syndrome; use for the treatment of seizures in patients with tuberous sclerosis complex, use for the treatment of seizures associated with tuberous sclerosis complex in patients taking everolimus, use for the treatment of seizures associated with dravet syndrome; use for the treatment of seizures associated with tuberous sclerosis complex; use for the treatment of seizures associated with lennox-gastaut syndrome.
Drug patent challenges can be filed against Epidiolex from 2022-09-28.
The generics of Epidiolex are possible to be released after 01 March, 2041.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10195159 | GW RES LTD | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
May, 2022
(10 months ago) | |
| US11096905 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Oct, 2035
(12 years from now) | |
| US11207292 | GW RES LTD | Cannabidiol preparations and its uses |
Apr, 2039
(16 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9956186 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10092525 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US9956183 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10111840 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10137095 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10603288 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10709671 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10709674 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US9956184 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US9956185 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US9949937 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10849860 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10966939 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10709673 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US11154516 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US11357741 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US11311498 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US11446258 | GW RES LTD | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(12 years from now) | |
| US10918608 | GW RES LTD | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(12 years from now) | |
| US11400055 | GW RES LTD | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(12 years from now) | |
| US11065209 | GW RES LTD | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(12 years from now) | |
| US11406623 | GW RES LTD | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(17 years from now) | |
| US11160795 | GW RES LTD | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(17 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 28, 2023 |
| Orphan Drug Exclusivity (ODE) | Jul 31, 2027 |
| New Patient Population (NPP) | Jul 31, 2023 |
Drugs and Companies using CANNABIDIOL ingredient
NCE-1 date: 2022-09-28
Market Authorisation Date: 28 September, 2018
Treatment: Use for the treatment of convulsive seizures in patients with lennox gastaut syndrome; Use for the treatment of drop seizures in patients with dravet syndrome; Use in combination with clobazam for the...
Dosage: SOLUTION;ORAL
EPIDIOLEX family patents
42
United States
21
United Kingdom
15
Australia
15
Japan
10
European Union
9
Mexico
9
Canada
8
Israel
5
Brazil
4
Spain
3
Poland
3
China
2
Denmark
2
Hong Kong
2
Slovenia
2
Lithuania
2
Hungary
2
Croatia
2
Portugal
2
Korea, Republic of
2
RS
1
Austria
1
Taiwan, Province of China
1
EA
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic